Coverage initiation: Social media lit up following news that a prominent bank launched coverage on the biotech company with an overweight rating and a price target of $68. Observers highlighted the potential for upcoming clinical data releases to drive momentum into the fourth quarter. Discussions emphasized strategic positioning amid sector peers.
Investor chatter: Participants shared notes on recent gains from related holdings, with some reallocating proceeds toward this ticker ahead of key milestones. The tone reflected measured optimism around product development timelines without overstatement. Overall exchanges stayed focused on fundamentals and timelines.
Note: This discussion summary was generated from an AI condensation of post data.
Definium Therapeutics Insider Trading Activity
Definium Therapeutics insiders have traded $DFTX stock on the open market 8 times in the past 6 months. Of those trades, 0 have been purchases and 8 have been sales.
Here’s a breakdown of recent trading of $DFTX stock by insiders over the last 6 months:
- ROBERT BARROW (Chief Executive Officer) has made 0 purchases and 2 sales selling 53,639 shares for an estimated $1,766,476.
- MARK SULLIVAN (Chief Legal Officer) has made 0 purchases and 2 sales selling 23,710 shares for an estimated $783,416.
- DANIEL KARLIN (Chief Medical Officer) has made 0 purchases and 2 sales selling 18,053 shares for an estimated $599,968.
- BRANDI ROBERTS (Chief Financial Officer) sold 3,013 shares for an estimated $135,675
- MATTHEW T. WILEY (Chief Commercial Officer) sold 2,867 shares for an estimated $129,101
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
Definium Therapeutics Hedge Fund Activity
We have seen 211 institutional investors add shares of Definium Therapeutics stock to their portfolio, and 21 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BLACKROCK, INC. added 8,480,230 shares (+inf%) to their portfolio in Q1 2026, for an estimated $156,163,435
- AVORO CAPITAL ADVISORS LLC added 5,000,000 shares (+inf%) to their portfolio in Q1 2026, for an estimated $92,075,000
- DEEP TRACK CAPITAL, LP added 3,000,000 shares (+inf%) to their portfolio in Q1 2026, for an estimated $55,245,000
- GEODE CAPITAL MANAGEMENT, LLC added 2,495,399 shares (+inf%) to their portfolio in Q1 2026, for an estimated $45,952,772
- STATE STREET CORP added 2,471,873 shares (+inf%) to their portfolio in Q1 2026, for an estimated $45,519,541
- OCTAGON CAPITAL ADVISORS LP added 2,440,000 shares (+inf%) to their portfolio in Q1 2026, for an estimated $44,932,600
- COMMODORE CAPITAL LP added 2,000,000 shares (+inf%) to their portfolio in Q1 2026, for an estimated $36,830,000
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
Definium Therapeutics Price Targets
Multiple analysts have issued price targets for $DFTX recently. We have seen 10 analysts offer price targets for $DFTX in the last 6 months, with a median target of $57.5.
Here are some recent targets:
- Paul Matteis from Stifel set a target price of $60.0 on 07/08/2026
- Sumant Kulkarni from Canaccord Genuity set a target price of $58.0 on 06/30/2026
- Justin Walsh from Jones Trading set a target price of $74.0 on 06/24/2026
- Christopher Chen from Baird set a target price of $57.0 on 06/23/2026
- Ami Fadia from Needham set a target price of $50.0 on 06/23/2026
- Marc Goodman from Leerink Partners set a target price of $52.0 on 06/22/2026
- Jay Olson from Oppenheimer set a target price of $60.0 on 06/22/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
